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Breast conservation treatment in Hong
Kong—early results of 203 patients:
retrospective study
Objective. To study the clinical outcomes of patients with invasive or non-
invasive breast cancer after breast conservation treatment.
Design. Retrospective study.
Setting. Clinical oncology department of a public hospital, Hong Kong.
Patients. Two hundred and three patients who received postlumpectomy radio-
therapy at the Pamela Youde Nethersole Eastern Hospital between January 1994
and June 1999.
Interventions. Adjuvant radiotherapy with or without systemic adjuvant
treatment.
Main outcome measures. Actuarial local control rate, progression-free survival
rate, disease-specific survival rate, and cosmetic score.
Results. The median follow-up was 3.5 years. Two of the 25 patients with carcin-
oma in situ only developed local recurrence; the 5-year actuarial local control
rate was 91.3%. Among the 178 patients with invasive cancer, seven had a local
recurrence and 12 developed distant metastases without local failure. The 5-year
actuarial local control, progression-free survival, and disease-specific survival
rates for patients with invasive cancer were 95.5%, 85.8%, and 95.2%,
respectively. The risk of local recurrence was significantly increased for younger
patients (age <40 years) and those with positive final margins. Cosmetic scores
were rated good to excellent by 95.6% of patients.
Conclusions. The early clinical outcomes of these patients are comparable
to those in large overseas trials, which have demonstrated the equivalence of
mastectomy and breast conservation treatment in terms of survival. In addition
to mastectomy, with or without breast reconstruction, breast conservation
treatment should be offered as an alternative to suitable Chinese women. To
maximise local control, further excision or mastectomy is recommended for
patients with positive final margins.
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Introduction
Breast conservation treatment (BCT), with its cosmetic and
psychological advantages, has been increasingly used in
the past 20 years. Following the demonstration in the late
1980s of the equivalence of BCT and mastectomy in terms
of survival outcome in randomised clinical studies,1-4 BCT
has been widely accepted as one of the standard treatment
options for early invasive breast cancer. For stages I and II
disease, breast conservation rates in the United States
rose from 32.8% in 1985 to 44.1% in 1994. Similarly, the
National Surgical Adjuvant Breast and Bowel Project
(NSABP) B-17 study 5 indicates that local excision and breast
irradiation are acceptable alternatives to mastectomy for
patients with localised ductal carcinoma in situ (DCIS).
Due to the relatively smaller breast size of Chinese
women, BCT has long been considered unsuitable for most
patients in Hong Kong.6 The first large and local series
of BCT was reported by Kwan et al7 in 1996. Fifty-four
patients with stage I or II breast cancer were treated with
BCT at the Prince of Wales Hospital between 1987 and
1994. At a median follow-up of 1.94 years, one patient
developed local recurrence, one had regional relapse, and
five developed distant metastases. Various hypofractionated
radiotherapy schemes and boosting techniques (electron,
iridium implant, and fractionated high-dose rate brachy-
therapy) were applied to these patients, making interpreta-
tion difficult. Cosmetic outcomes were not reported.
Given that the above series was collected over a 7-year
period at a large regional public hospital, BCT was obvi-
ously not a common mode of breast cancer management in
the early 1990s. Reasons for this included the scarcity of
small lesions detected at screening, long waiting times for
radiotherapy, and the bias of both surgeons and patients.
However, with the increase in number of radiotherapy
machines and the promotion of BCT by breast surgeons,
oncologists, and patient support groups, the situation has
changed considerably, and more and more patients are now
treated with breast conservation. In 2000 alone, 56 patients
received radiotherapy for BCT in the Department of Clinical
Oncology at the Pamela Youde Nethersole Eastern Hospital.
The Department of Clinical Oncology of Pamela Youde
Nethersole Eastern Hospital was established in 1994. By
examining the clinical outcomes of more than 200 patients
treated from 1994 to 1999, we aim to find out whether it is
safe to offer BCT as an alternative to mastectomy in our
local population, and whether the treatment outcomes of
our patients are comparable to those of western countries.
Methods
Patient characteristics and selection
Data analysis was carried out in February 2002. The
medical records of all female patients who received post-
lumpectomy radiotherapy for BCT at the Pamela Youde
Nethersole Eastern Hospital between January 1994 and
June 1999 were reviewed, including patients treated for
DCIS alone.
In this group of 203 patients, 141 were referred by pub-
lic hospitals and 62 were referred by private or overseas
surgeons. Their ages ranged from 25 to 90 years (median,
44 years). One hundred and ninety-six (96.6%) patients were
Chinese, three were other Asians, and four were Caucasians.
The median duration of follow-up was 3.5 years (range,
0.2-7.9 years). One patient was followed up for 0.2 years
only because she returned to her home country soon after
completion of radiotherapy.
Surgical and pathological characteristics
Twenty-five patients had DCIS only. The characteristics of
the other 178 patients with invasive carcinoma are listed
in Table 1. Ninety-three patients had stage I (T1N0) dis-
ease and another five had T1 lesions with unknown axillary
status (T1Nx). The remaining 80 patients had stage II
disease.
The case selection criteria and treatment largely followed
the 1992 Standards for breast conservation treatment
jointly developed by the American College of Radiology,
American College of Surgeons, College of American
Pathologists, and Society of Surgical Oncology.8 Negative
microscopic margins were required before radiotherapy.
Patients referred with positive microscopic margins were
advised to have further excision before radiotherapy.
Indeed, some patients had already had re-excision to achieve
negative or wider margins before referral. Overall, 193
patients had negative final microscopic margins, including
44 who had margins that were considered to be close
(ie <3 mm). The remaining 10 patients had positive final
margins. Further excision or mastectomy was not performed
in these patients, either because of refusal by the patient, or
because of technical difficulties in further resecting the
deep margin close to the chest wall.
Axillary dissection was not done for patients with
DCIS only. It was, however, performed for all patients
with invasive cancer, except five patients who refused this
operation. Since the level of axillary dissection was not
clearly stated in many referrals, this factor was not further
analysed.
Radiotherapy
All but one patient received whole breast irradiation after
breast conserving surgery. The exception was a 74-year-old
woman who, on account of her lesion being located high
up in the chest wall, received radiotherapy to the tumour
bed only (35 Gy in 10 fractions). For all other patients,
breast boards were used for the daily treatment. Wedged
tangential opposing fields with 6 MV photons (linear
accelerators) were used to deliver 50 Gy in 2 Gy daily frac-
tions over 5 weeks. No bolus was used. Electron boost to
the tumour bed was routinely given for all patients except
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those with more than 1 cm–free microscopic margins on
all sides. The routine boost dose was 10 Gy in five daily frac-
tions. For those with microscopic margins of 1 mm or less,
a higher dose of 16 Gy in eight daily fractions was given.
Interstitial brachytherapy was not used for boosting. Al-
together, 174 patients received electron boost to the tumour
bed, including 24 who received the boost dose of 16 Gy.
Regional radiotherapy to the ipsilateral axilla and
supraclavicular fossa was offered to those patients with
invasive cancer who had more than three positive axillary
nodes, gross extranodal extension, or no axillary dissection.
A separate anterior field was used to deliver 50 Gy in 2 Gy
daily fractions. No posterior axillary field was used. The
internal mammary chain (IMC) was not specifically
included, although it might have been partially covered by
the tangential opposing fields. No separate IMC field
was used. Among those 178 patients with invasive cancers,
17 received additional regional irradiation. Another three
refused this form of treatment because of concerns over
arm lymphoedema.
Radiotherapy was started after a median duration of
5 weeks (range, 2-13 weeks) after surgery unless it had
to be deferred until the completion of chemotherapy.
The relatively long postsurgical gap (>6 weeks) for some
patients was due either to delays in initiating referral
or wound healing problems. Patients receiving chemo-
therapy prior to radiotherapy had a postsurgical gap of
14 to 48 weeks, depending on the chemotherapy regimens
used.
Systemic therapies
Patients considered to have an increased risk of distant
failure were offered systemic adjuvant therapies. Some
patients received such therapies from other public hospitals
or private doctors. A total of 149 patients with invasive
cancer received additional systemic adjuvant therapy—79
received tamoxifen alone; 40 received both tamoxifen and
chemotherapy; and 30 received chemotherapy alone.
Sequencing of chemotherapy with radiotherapy
Patients considered to be at high risk of systemic failure
were given chemotherapy within a few weeks of surgery,
either concurrent with, or completed before, radiotherapy.
Patients at relatively lower risk of systemic failure received
chemotherapy after completion of radiotherapy. Among
the 70 patients who received chemotherapy, nine were
treated preoperatively to downsize the tumour, 21 were
treated concurrently with radiotherapy, 15 were treated
adjuvantly before radiotherapy, and 25 were treated
after the completion of radiotherapy. The impacts of
sequencing on local and distant failure rates are reported
separately.
Table 1. Prognostic factors for local and distant/regional failure in patients with invasive cancers
Patients Local failure* Distant/regional failure
No. (%) 5-Year actuarial rate (%) P value 5-Year actuarial rate (%) P value
Age (years)
≤40 55 12.0 - 22.0 -
41-60 102 1.0 0.03 4.5 0.09
>61 21 0 - 5.0 -
Pathological stage
Stage I (T1N0) 93 3.0 - 2.5 -
Stage II 80 7.0 0.39 21.0 0.01
T1N1 29 - - - -
T2N0 28 - - - -
T2N1 21 - - - -
T2Nx 2 - - - -
T1Nx 5 0 - 0 -
Histological grade
I 34 0 - 0 -
II 54 2.0 0.26 14 0.34
III 60 8.5 - 14 -
NA† 30 5.0 - 10 -
Number of involved nodes
0 128 4.0 - 6 -
1-3 37 0 0.051 22 0.1
>3 13 23.0 - 31 -
Oestrogen receptor status
ER+‡ or PR+§ 110 5.0 - 4 -
ER-❘❘ and PR-¶ 46 7.0 0.04 30 0.0001
Unknown 22 0 - 5 -
Final margin status
≥3 mm 130 2.0 - 11 -
>0 but <3 mm 38 10.0 0.01 12 0.91
Positive 10 21.0 - 10 -
* as first site of failure
† NA not applicable or not assessable
‡ ER+ oestrogen receptor–positive
§ PR+ progesterone receptor–positive
❘❘ ER- oestrogen receptor–negative
¶ PR- progesterone receptor–negative
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Follow-up and reassessment
Patients were followed up every 2 to 3 months in the first
2 years, and then every 4 to 6 months in the third to fifth
years. Annual mammograms were routinely used to detect
early recurrence. A 10-point scoring system was used
to record the breast cosmesis at follow-up (Table 2). The
score was rated as excellent (9-10), good (7-8), fair (5-6),
or poor (1-4). The score was given by the patients and
by the attending clinical oncologist/trainee. A simple
and commonly accepted definition of arm lymphoedema
was used, namely, a 2 cm or more difference in mid-arm
circumference.
Statistical methods
Actuarial local control, progression-free survival, and
disease-specific survival rates were estimated using Kaplan-
Meier survival curves. The date of last local excision
was used as the beginning of the follow-up interval. Using
log-rank tests, the following clinical and histopathological
factors were analysed for their ability to predict for local
failure and distant/regional failure: age, pathological stage,
histological grade, number of involved nodes, oestrogen
receptor status, and final margin status.
Results
Local and distant failure
Ductal carcinoma in situ
The median follow-up for the 25 patients with DCIS
only was 3.4 years (range, 2.6-6.7 years). Two (8.0%)
developed in-breast recurrence, one with DCIS only on
salvage mastectomy while the other was still being sched-
uled for operation at the time of the last data entry. The
5-year actuarial local control rate was 91.3%. There was
no distant or regional failure in this group.
Invasive breast cancer
The median follow-up for the 178 patients with invasive
cancer was 3.6 years (range, 0.2-7.9 years). Seven (3.9%)
suffered local recurrence, five with local recurrence only
and the other two with regional or distant secondaries
simultaneous with the local recurrence. Local recurrences
were detected at 12 to 76 months after surgery. All five
patients with local recurrence had only undergone salvage
mastectomy: three had invasive ductal carcinomas, one had
DCIS with micro-invasion, and one had DCIS only.
Of the five patients with local recurrence only, two
were detected at a late stage. In one of the patients, gross
skin infiltration was detected soon after childbirth. In
another patient, there was extensive local recurrence requir-
ing flap reconstruction in salvage surgery. The first patient
had a good response to preoperative chemotherapy and
remained disease-free after salvage mastectomy. For the
second patient, however, salvage surgery was unsuccessful
and she developed further local recurrence and lung
secondaries 8 months later. Overall, four of the five patients
presenting with local failure only remained disease-free
after salvage treatment.
The risk of disease failure in relation to the patient
and histopathological characteristics are shown in Table 1.
Despite the higher boost dose given, patients with positive
microscopic margins still had a significantly higher risk of
5-year local failure compared to those with close (<3 mm),
but clear, margins, and those with negative margins (21%
versus 10% and 2%, respectively; P=0.01).
Our experience is similar to overseas studies9,10 in that the
risk of local recurrence was significantly higher for younger
patients. The 5-year actuarial local failure rates for patients
aged 40 years or younger, 41 to 60 years, and 61 years or
older were 12%, 1%, and 0%, respectively (P=0.03).
Twelve (6.7%) patients developed distant metastases
without any signs of local recurrence. As expected, oestro-
gen receptor–negative tumours had a significantly higher
5-year actuarial distant failure rate compared with oestro-
gen receptor–positive tumours (30% versus 4%, P=0.0001);
the same was true for stage II tumours compared with stage
I tumours (21.0% versus 2.5%, P=0.01).
The 5-year actuarial local control and progression-free
survival rates for patients with invasive cancer were 95.5%
and 85.8%, respectively (Fig). Since most patients with in-
breast recurrence only remained disease-free after salvage
treatment, the 5-year actuarial disease-specific survival rate
remained high at 95.2%.
Table 2. Scoring system of breast cosmesis
Excellent (9-10) Treated breast is almost identical to the
untreated breast
Good (7-8) Minimal difference between the treated
and untreated breasts
Fair (5-6) Obvious difference between the treated
and untreated breasts
Poor (1-4) Major functional and aesthetic sequelae
in the treated breast
Fig. 5-Year actuarial local control and progression-free survival
rates among 178 patients with invasive cancer undergoing
breast conservation treatment
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Treatment complications
Radiotherapy was well tolerated and completed unevent-
fully in all but two patients, one stopped radiotherapy
prematurely at 56 Gy for personal reasons and the other
stopped prematurely at 46 Gy after developing a breast
abscess. Transient grade 1 to 2 skin reactions were common,
but there were no other significant acute side-effects. There
were no cases of radiation pneumonitis, rib fractures,
matchline fibrosis, or brachial plexopathy.
Arm lymphoedema developed and persisted in three
(17.6%) of the 17 patients who received additional regional
irradiation. Three (1.6%) of the remaining 186 patients who
did not receive additional regional irradiation also devel-
oped mild and transient arm lymphoedema. In other words,
arm lymphoedema developed in only six (3.0%) patients.
Cosmesis
The cosmetic scores are shown in Table 3. Seventeen
patients did not have any cosmetic assessment recorded
and three had scores given by doctors only. The average
(out of 10) cosmetic scores given by patients and doctors
were 8.07 and 8.04, respectively. The cosmetic results
were rated as either good or excellent by 95.6% of patients.
Eight patients rated their cosmetic results as either poor
or fair.
Discussion
Options for the surgical management of primary breast tu-
mours include breast conserving surgery plus radiation
therapy, mastectomy plus reconstruction, and mastectomy
alone. Despite recent advances in reconstructive techniques,
BCT is still more widely used to preserve the body contour.
For example, throughout the study period, only 21 patients
referred for systemic treatment or radiotherapy had breast
reconstruction performed. Preferences on the part of the
patient and/or the surgeon, and the limited availability of
experienced plastic surgeons might all be contributing
factors.
For invasive breast cancer, radiotherapy is widely
accepted as one of the essential component in BCT.8,11
Breast conserving surgery without radiation therapy has
been compared with breast conserving surgery followed by
radiation therapy in four prospective randomised trials,2,12-14
all of which demonstrated a higher in-breast recurrence
rate with breast conserving surgery alone. Thus far, we still
cannot reliably identify a subgroup of patients that do
not require radiotherapy. The recently reported results of
the NSABP B-21 study15 also support the belief that even
small tumours with clear resection margins require
radiotherapy.
Similarly, for DCIS after lumpectomy, the NSABP
B-17 study5 showed that the occurrence of invasive cancer
decreased from 13.4% to 3.9% with the addition of radiation,
and that of recurrent DCIS was reduced from 13.4% to
8.2%. Only 1% of patients in the NSABP study died from
breast cancer, which was similar to the historical control
rate (after mastectomy). This trial indicates, therefore, that
local excision, together with breast irradiation, is an accept-
able therapy for localised DCIS. It did not identify any
subset of patients that did not benefit from the addition
of radiation therapy.
The 5-year actuarial local control and disease-specific
survival rates in our patients are comparable to those
reported in large overseas studies.2,3,5 In a series from the
Netherlands consisting of 1360 patients with invasive cancer,
the 5- and 10-year local recurrence risks were 8% and 12%,
respectively.9 Young age (<45 years) is a major risk factor
and there is a gradual, but significant, decrease in local
recurrence with advancing age. Local relapse rates of 15%
to 20% after 15 years have been reported in a series with
extended follow-up, and the annual rate of local relapse was
generally estimated to be 1%.16
With careful planning of radiotherapy and restriction
on the volume of lung tissues irradiated, none of our pa-
tients developed clinical radiation pneumonitis, brachial
plexopathy, or matchline fibrosis. In addition, the overall
incidence of arm lymphoedema in this series (3%) is lower
than that reported in overseas series of BCT that have
used a similar definition for lymphoedema (3% versus 14%
to 16%, respectively).17,18 More than half of the patients
in the overseas studies did not receive regional irradiation.
Although reports relate the occurrence of arm lymphoedema
to older age, obesity, and surgical techniques, axillary
irradiation is still the most important predictor.19,20 We
Table 3. Cosmetic scores in 203 breast conservation treatment patients
Cosmetic score Self-assessment by patient Assessment by clinical oncologist
No. (%) No. (%)
10 9 (4.4) 7 (3.4)
9 52 (25.6) 54 (26.6)
8 76 (37.4) 77 (37.9)
7 38 (18.7) 40 (19.7)
6 5 (2.5) 4 (2.0)
5 2 (1.0) 3 (1.5)
4 1 (0.5) 1 (0.5)
1-3 0 (0) 0 (0)
Not recorded 20 (9.9) 17 (8.4)
Median cosmetic score* 8 8
Average cosmetic score* 8.07 8.04
* of patients with known scores
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believe that our strict selection criteria for axillary radio-
therapy contributed to the low rate of arm lymphoedema.
However, since late radiation damage and carcinogenesis
may take years to develop, longer follow-up is required to
conclusively report on the radiotherapy-related side-effects
in these patients.
The role of boost dose to the tumour bed remains
controversial. The results of a randomised French study
suggest that a 10 Gy boost (with electron beam in four
fractions) after whole breast irradiation (50 Gy in 2.5
fractions) may significantly reduce the 5-year local recur-
rence rate from 4.5% to 3.6%.21 The boost group had a
higher rate of grades 1 and 2 telangiectasia (12.4% versus
5.9%), but no difference was seen in the patient-assessed
cosmetic score. Similarly, the European Organisation for
the Research and Treatment of Cancer (EORTC) randomised
trial presented at the Second European Breast Cancer
Conference (Brussels, 2000) showed that a boost dose
significantly reduced the 5-year local recurrence rate
for patients with negative margins from 6.8% to 4.3%
(P<0.0001).22 As the surgical margins in many Chinese pa-
tients are quite close, we advocate routine boosting except
for those with microscopic margins of more than 1 cm.
Electron boosting is simple, non-invasive, and effective.
In this study, final resection margin status correlated
with the risk of local recurrence. This finding is consistent
with that reported by other studies. For example, a recent
retrospective study from France found a high 5-year local
recurrence rate of 20% in 152 node-negative patients with
positive margins after conservative surgery who received
radiotherapy without chemotherapy (which might have
reduced the local recurrence rate).23 This study confirmed
that positive margins increased the risk of local recurrence.
The risk was increased regardless of the extent (single or
multiple) and histology (infiltrating or intraductal carcin-
oma) of the positive margins. Although 64% of patients in
this series received doses ≥70 Gy, no dose effect was ob-
served on the local control rate. The authors concluded that
radiotherapy could not be considered as an alternative to
re-excision for these patients.
Likewise, Wazer et al10 showed that dose escalation of
breast conserving irradiation yielded low local recurrence
rates for close (>0 to ≤2 mm) and intermediate (2.1 to
5 mm) margins, but not for positive margins. The overall
mean annual local failure rate in the first 4 years was
exceptionally low at 0.25%, but it rose to a mean of 1.1% in
subsequent years. There was a significant increase in the
relative risk of local failure at age 45 years or below (range,
11.1-17.4 years), irrespective of final margin status.
These investigators concluded that although graded
dose escalation according to final margin status resulted
in a low risk of early local recurrence within the first 5
years, this strategy was unable to completely overcome the
long-term adverse influence of young age and positive
margins.
As to whether the adverse effect of positive margins
can be overcome with a higher boost dose delivered by
brachytherapy, excellent local control and acceptable
cosmetic outcomes have been reported with fractionated
interstitial high dose rate brachytherapy boost.24 However,
only six of the 18 patients in this small series had focally
positive final margins; the remainder had close, but clear,
margins.
In contrast with the previous belief that patients with
focal margin involvement and no extensive intraductal
carcinoma might reasonably be considered for BCT, we
strongly recommend patients with positive margins to have
further excision or mastectomy if possible. Further dose
escalation, even with interstitial brachytherapy, is likely to
be inadequate, and local recurrence is associated with a
higher risk of distant metastasis and death.9
Should re-excision be performed for patients with
close, but clear, margins? Despite years of discussion, the
question of what is an acceptable margin status has not been
resolved yet. In our series, patients with close (<3 mm), but
clear, margins also had an increased risk of local recurrence
(10% at 5 years). The closest margins in Chinese women
are frequently the deep ones, and re-excision, or even
mastectomy, might not help these patients. For some
patients, re-excision for wider margins would likely have
an adverse effect on the cosmesis. Patient preference,
potential impact on the cosmesis, and technical feasibility
(especially for close deep margins) are all important
considerations in deciding whether or not these patients
should undergo re-excision. A more generous initial
excision to avoid the need for a re-excision for positive or
close margins is advised.
Conclusion
The early clinical outcomes of these patients are compar-
able to those in large overseas trials that have demonstrated
the equivalence of mastectomy and BCT in terms of sur-
vival outcomes. In addition to mastectomy, with or without
breast reconstruction, BCT should be offered as an alter-
native to suitable Chinese women. To maximise the local
control, further excision or mastectomy is recommended for
patients with positive final margins.
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